| 0.311 0.008 (2.64%) | 04-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.47 | 1-year : | 0.59 |
| Resists | First : | 0.4 | Second : | 0.5 |
| Pivot price | 0.32  |
|||
| Supports | First : | 0.24 | Second : | 0.2 |
| MAs | MA(5) : | 0.31 |
MA(20) : | 0.33 |
| MA(100) : | 1.26 |
MA(250) : | 2 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 22.2 |
D(3) : | 25.8 |
| RSI | RSI(14): 41.6 |
|||
| 52-week | High : | 14.5 | Low : | 0.24 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VERO ] has closed above bottom band by 32.9%. Bollinger Bands are 94.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 25 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.31 - 0.31 | 0.31 - 0.31 |
| Low: | 0.27 - 0.27 | 0.27 - 0.27 |
| Close: | 0.31 - 0.31 | 0.31 - 0.31 |
Venus Concept Inc. is a medical technology firm that specializes in offering a range of innovative minimally and non-invasive solutions for medical aesthetics and hair restoration. Operating both domestically in the U.S. and internationally, the company is responsible for the development, market introduction, and ongoing provision of these advanced technologies and associated services. Its comprehensive product lineup features several cutting-edge devices: Venus Legacy: A non-invasive system primarily used in dermatological and general surgical procedures for female patients. Venus Versa: A versatile, multi-application platform designed for various aesthetic and cosmetic treatments. Venus Viva: A portable and advanced fractional radiofrequency (RF) system utilized in dermatological procedures for skin ablation and resurfacing. Venus Fiore: Employs non-thermal RF technology, combined with massage and magnetic field pulses, to address a variety of medical conditions. Venus Bliss: Targets non-invasive lipolysis of the abdomen and flanks, suitable for individuals with a body mass index (BMI) of 30 or below. Venus Glow: A specialized dermabrasion device aimed at enhancing overall skin appearance. NeoGraft: Provides advanced hair restoration using an automated Follicular Unit Extraction (FUE) and implantation system. Venus Velocity & Venus Epileve: These devices facilitate permanent hair removal, reduction, and the treatment of pseudofolliculitis barbae. ARTAS iX: A robotic system that assists physicians during hair transplantation by automating the identification, extraction, and implantation of follicular units from the scalp, as well as the creation of recipient sites. The company's corporate headquarters are located in Toronto, Canada.
Wed, 01 Apr 2026
Venus Concept Announces Completion of Common Stock Sale and Short-Form Merger - Yahoo Finance
Wed, 21 Jan 2026
This Microcap Company Announced Plans To Delist Just Days After The Stock Surged 450% — What Happened? - Stocktwits
Wed, 21 Jan 2026
Venus Concept Announces Intention to Voluntary Delist from Nasdaq and Deregister with SEC - Yahoo Finance
Wed, 21 Jan 2026
Venus Concept Inc. Announces Voluntary Delisting from NASDAQ and Deregistration with SEC | VERO Stock News - Quiver Quantitative
Wed, 21 Jan 2026
Venus Concept stock plummets after announcing Nasdaq delisting plans - Investing.com
Sat, 17 Jan 2026
Venus Concept Shares Soar Over 200% Amid Market Buzz - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 14.5 (%) |
| Shares Short | 173 (K) |
| Shares Short P.Month | 94 (K) |
| EPS | -45.26 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.44 |
| Profit Margin | -92.8 % |
| Operating Margin | -69 % |
| Return on Assets (ttm) | -32.5 % |
| Return on Equity (ttm) | -794.6 % |
| Qtrly Rev. Growth | -8.2 % |
| Gross Profit (p.s.) | 20.37 |
| Sales Per Share | 31.65 |
| EBITDA (p.s.) | -16.61 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0.21 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.03 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|